Free Trial
NASDAQ:THAR

Tharimmune Q1 2025 Earnings Report

Tharimmune logo
$3.52 +0.17 (+5.07%)
As of 05/22/2026

Tharimmune EPS Results

Actual EPS
-$0.99
Consensus EPS
-$0.84
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Tharimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tharimmune Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Sunday, May 11, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Tharimmune's Q2 2026 earnings is estimated for Wednesday, June 3, 2026, based on past reporting schedules

Earnings Documents

Tharimmune Earnings Headlines

Tharimmune (NASDAQ:THAR) Stock Price Down 3.5% - What's Next?
Tharimmune Inc.
The SpaceX filing is public. The window is closing.
SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.tc pixel
See More Tharimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tharimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tharimmune and other key companies, straight to your email.

About Tharimmune

Tharimmune (NASDAQ:THAR), a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

View Tharimmune Profile